Unknown

Dataset Information

0

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.


ABSTRACT: Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.

SUBMITTER: Kunze KL 

PROVIDER: S-EPMC8357797 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.

Kunze Katie L KL   Johnson Patrick W PW   van Helmond Noud N   Senefeld Jonathon W JW   Petersen Molly M MM   Klassen Stephen A SA   Wiggins Chad C CC   Klompas Allan M AM   Bruno Katelyn A KA   Mills John R JR   Theel Elitza S ES   Buras Matthew R MR   Golafshar Michael A MA   Sexton Matthew A MA   Diaz Soto Juan C JC   Baker Sarah E SE   Shepherd John R A JRA   Verdun Nicole C NC   Marks Peter P   Paneth Nigel S NS   Fairweather DeLisa D   Wright R Scott RS   van Buskirk Camille M CM   Winters Jeffrey L JL   Stubbs James R JR   Senese Katherine A KA   Pletsch Michaela C MC   Buchholtz Zachary A ZA   Rea Robert F RF   Herasevich Vitaly V   Whelan Emily R ER   Clayburn Andrew J AJ   Larson Kathryn F KF   Ripoll Juan G JG   Andersen Kylie J KJ   Lesser Elizabeth R ER   Vogt Matthew N P MNP   Dennis Joshua J JJ   Regimbal Riley J RJ   Bauer Philippe R PR   Blair Janis E JE   Casadevall Arturo A   Carter Rickey E RE   Joyner Michael J MJ  

Nature communications 20210811 1


Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hyp  ...[more]

Similar Datasets

| S-EPMC9295964 | biostudies-literature
| S-EPMC11783493 | biostudies-literature
| S-EPMC7753739 | biostudies-literature
| S-EPMC9252887 | biostudies-literature
| S-EPMC7499592 | biostudies-literature
| S-EPMC8447161 | biostudies-literature
| S-EPMC7661912 | biostudies-literature
| S-EPMC8918483 | biostudies-literature
| S-EPMC8251132 | biostudies-literature
| S-EPMC8013201 | biostudies-literature